For Immediate Release
Chicago, IL – April 1, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc.
WMT
, Adobe Inc.
ADBE
, Bristol-Myers Squibb Company
BMY
, BHP Group Ltd.
BHP
and Micron Technology, Inc.
MU
.
Here are highlights from Thursday’s Analyst Blog:
Top Stock Reports for Walmart, Adobe & Bristol Myers
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Walmart Inc., Adobe Inc., and Bristol-Myers Squibb Company. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
Walmart
shares have lagged the Zacks Retail – Supermarkets industry over the past one year period (+12.2% vs. +15.4%), reflecting the high costs incurred by the company related to supply chain, wages and COVID-19 that are weighing on the outlook for margins. The company envisions operating income and earnings per share to decline in the first quarter, as it cycles stimulus gains witnessed last year, along with higher wages for this year.
Walmart continues to benefit from its robust omnichannel efforts and last-mile delivery capabilities. With more customers and members returning to stores and clubs, demand seems to be strong. Reflection of the same was visible in fourth-quarter results, wherein both top and bottom lines grew year over year.
(You can
read the full research report on Walmart here >>>
)
Adobe
shares have gained +52.8% over the past two periods against the Zacks Computer – Software industry’s gain of +91%. The Zacks analyst believes that the company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products drove the top-line growth. Further, rising subscription revenues and solid momentum across the mobile apps remained major positives. Growth in emerging markets, robust online video creation demand and solid adoption of Acrobat are tailwinds.
Also, continued key customer wins of the company are contributing well. We remain optimistic about Adobe’s market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and strong Workfront momentum. However, the ongoing tensions between Russia and Ukraine remain major headwinds for Digital Media segment.
(You can
read the full research report on Adobe here >>>
)
Shares of
Bristol-Myers
have outperformed the Zacks Medical – Biomedical and Genetics industry over the past year (+20% vs. -27.7%). The Zacks analyst believes that strong performance of Eliquis and accelerated growth for Opdivo. Eliquis is the leading oral anticoagulant drug and continues to experience growth in its market share. The label expansion of Opdivo into indications of lung cancer, renal cancer and gastric cancer boosted sales. Revlimid continues to gain from demand for triple-based therapies and increasing treatment duration.
The approval of new drugs adds a new stream of revenues, which should boost growth in the coming quarters. The pipeline progress has been impressive and strategic collaborations will further expand the portfolio. Shares have outperformed the industry in the year so far. However, Revlimid is facing generic competition, which will adversely impact sales. Competition is stiff for Opdivo.
(You can
read the full research report on Bristol-Myers here >>>
)
Other noteworthy reports we are featuring today include BHP Group Ltd. and Micron Technology, Inc.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly
Earnings Trends
and
Earnings Preview
reports. If you want an email notification each time Sheraz publishes a new article, please
click here>>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report